2026 Q2 - tulosraportti
Vain PDF
24 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.- ·14.8.Soon Quarterly Report, so it would be nice if we could get some info about what the future looks out for the Company ;-).
I thought the report would come today, but now it's in 7 days. Was it Nordnet that had the wrong date or have they postponed the report again? Do you know? 
·13.8.Miris Holding develops and sells medical technology equipment for the analysis of human milk. The equipment is used in hospitals and Milk Banks to adapt nutrition for prematurely born children. Business model and market Unique position: The company is globally unique in having a medically approved analysis network/instrument for breast milk, which effectively removes direct competitors in the regulated market. Global reach: Over 500 instruments are installed in 54 countries via direct sales and distributors. Revenue streams: Hardware sales are supplemented by ongoing, recurring revenues from calibration, service, and consumables. Financial and technical status Growth vs. Liquidity: Miris shows progress in revenue and continuously receives orders from international research centers and hospitals, Financial status (Q1 2026) The latest financial figures from the company's Q1 2026 report show a company in a transitional phase characterized by macroeconomic headwinds, but with a stabilized cash position: Decline in net sales: Net sales for Q1 2026 amounted to 3,436 tkr. SEK, which is a decrease of approximately 25% compared to the same period in 2025 (4,585 tkr. SEK). Sluggishness in the American market: The company reports that the uncertain macroeconomic environment has led to longer decision-making processes and postponed investments at hospitals, especially in the USA. However, it has recently made exclusive agreements for market access in the Middle East, which strengthens Miris' position. Pipeline is intact: Management emphasizes that the postponed orders are not lost; the sales pipeline remains active. After the quarter's end, the company has seen increased activity in the form of new orders (including a new USA order in May 2026) and reinvestments from existing Nordic hospitals. Improved capital base: Through capital raises in 2025 (totaling approx. 25.3 million SEK), the company entered 2026 with a significantly stronger financial position, giving them peace of mind to mature the market. The medical potential in neonatal care The clinical foundation behind the Miris Human Milk Analyzer (HMA) is strong and addresses a critical, unmet need in neonatal intensive care units (NICU): Targeted Fortification: With Miris HMA, doctors can analyze the specific milk in minutes with just 3 ml of milk. This makes it possible to tailor the fortification (addition of extra protein or fat) precisely to the needs of each individual, prematurely born child. Clinical benefits: Studies and clinical feedback show that this precision nutrition reduces the risk of postnatal growth restriction, ensures better neurological development in extremely low birth weight (ELBW) infants, and can potentially shorten hospital stays, saving healthcare significant sums. Unique regulatory barrier: Miris remains the only company with FDA approval (obtained at the end of 2018) for clinical multi-analysis of breast milk in the USA. This provides an enormous competitive advantage, as it takes years for potential competitors to achieve the same medical validation. Summary and investment case The investment case in Miris balances a large medical potential with a sluggish commercial rollout: The medical value is undeniable, and the company owns the market regulatorily. The economic challenge, however, is hospitals' long budget and procurement cycles, which are further extended during economic uncertainty. However, the latest reports of reinvestments show that once a hospital has adopted the technology, it becomes an indispensable standard. Consumables business model Miris uses a classic "razor & blade" business model, which creates a growing stream of recurring revenues Primary sales: The hospital or milk bank makes a large one-time investment by purchasing the Miris Human Milk Analyzer (HMA) instrument itself, as well as associated hardware such as sonicators for sample preparation. Consumables: For the instrument to function correctly, deliver precise measurements, and comply with strict medical approvals, hospitals are forced to continuously purchase the company's own, specially developed consumables. These include: Miris Check: Calibration fluids for checking the instrument's zero setting. Miris Calibration Control Kit: Solutions with known concentrations of fat, protein, and carbohydrates for validation. Miris Cleaner: Specialized cleaning fluids that ensure milk residues do not damage the sensitive sensors. Miris Syringes: Specific disposable syringes approved for use in the machine. The more machines Miris gets installed around the world, the greater the automatic, ongoing sale of consumables becomes. These revenues generally have a higher margin (gross margin) than the hardware itself and give the company a more predictable earnings profile, which reduces dependence on long hospital budget cycles. The latest new orders are exciting and prove that Miris is on the right track. I look forward to the financial report.
- ·30.7.One can't really see orders pouring in, and very little info from the company :-).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
24 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.
- ·14.8.Soon Quarterly Report, so it would be nice if we could get some info about what the future looks out for the Company ;-).I thought the report would come today, but now it's in 7 days. Was it Nordnet that had the wrong date or have they postponed the report again? Do you know?
- ·13.8.Miris Holding develops and sells medical technology equipment for the analysis of human milk. The equipment is used in hospitals and Milk Banks to adapt nutrition for prematurely born children. Business model and market Unique position: The company is globally unique in having a medically approved analysis network/instrument for breast milk, which effectively removes direct competitors in the regulated market. Global reach: Over 500 instruments are installed in 54 countries via direct sales and distributors. Revenue streams: Hardware sales are supplemented by ongoing, recurring revenues from calibration, service, and consumables. Financial and technical status Growth vs. Liquidity: Miris shows progress in revenue and continuously receives orders from international research centers and hospitals, Financial status (Q1 2026) The latest financial figures from the company's Q1 2026 report show a company in a transitional phase characterized by macroeconomic headwinds, but with a stabilized cash position: Decline in net sales: Net sales for Q1 2026 amounted to 3,436 tkr. SEK, which is a decrease of approximately 25% compared to the same period in 2025 (4,585 tkr. SEK). Sluggishness in the American market: The company reports that the uncertain macroeconomic environment has led to longer decision-making processes and postponed investments at hospitals, especially in the USA. However, it has recently made exclusive agreements for market access in the Middle East, which strengthens Miris' position. Pipeline is intact: Management emphasizes that the postponed orders are not lost; the sales pipeline remains active. After the quarter's end, the company has seen increased activity in the form of new orders (including a new USA order in May 2026) and reinvestments from existing Nordic hospitals. Improved capital base: Through capital raises in 2025 (totaling approx. 25.3 million SEK), the company entered 2026 with a significantly stronger financial position, giving them peace of mind to mature the market. The medical potential in neonatal care The clinical foundation behind the Miris Human Milk Analyzer (HMA) is strong and addresses a critical, unmet need in neonatal intensive care units (NICU): Targeted Fortification: With Miris HMA, doctors can analyze the specific milk in minutes with just 3 ml of milk. This makes it possible to tailor the fortification (addition of extra protein or fat) precisely to the needs of each individual, prematurely born child. Clinical benefits: Studies and clinical feedback show that this precision nutrition reduces the risk of postnatal growth restriction, ensures better neurological development in extremely low birth weight (ELBW) infants, and can potentially shorten hospital stays, saving healthcare significant sums. Unique regulatory barrier: Miris remains the only company with FDA approval (obtained at the end of 2018) for clinical multi-analysis of breast milk in the USA. This provides an enormous competitive advantage, as it takes years for potential competitors to achieve the same medical validation. Summary and investment case The investment case in Miris balances a large medical potential with a sluggish commercial rollout: The medical value is undeniable, and the company owns the market regulatorily. The economic challenge, however, is hospitals' long budget and procurement cycles, which are further extended during economic uncertainty. However, the latest reports of reinvestments show that once a hospital has adopted the technology, it becomes an indispensable standard. Consumables business model Miris uses a classic "razor & blade" business model, which creates a growing stream of recurring revenues Primary sales: The hospital or milk bank makes a large one-time investment by purchasing the Miris Human Milk Analyzer (HMA) instrument itself, as well as associated hardware such as sonicators for sample preparation. Consumables: For the instrument to function correctly, deliver precise measurements, and comply with strict medical approvals, hospitals are forced to continuously purchase the company's own, specially developed consumables. These include: Miris Check: Calibration fluids for checking the instrument's zero setting. Miris Calibration Control Kit: Solutions with known concentrations of fat, protein, and carbohydrates for validation. Miris Cleaner: Specialized cleaning fluids that ensure milk residues do not damage the sensitive sensors. Miris Syringes: Specific disposable syringes approved for use in the machine. The more machines Miris gets installed around the world, the greater the automatic, ongoing sale of consumables becomes. These revenues generally have a higher margin (gross margin) than the hardware itself and give the company a more predictable earnings profile, which reduces dependence on long hospital budget cycles. The latest new orders are exciting and prove that Miris is on the right track. I look forward to the financial report.
- ·30.7.One can't really see orders pouring in, and very little info from the company :-).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
24 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 28.8. | ||
2026 Q1 - tulosraportti 28.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 27.11.2025 | ||
2025 Q2 - tulosraportti 20.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·28.8."We are entering the autumn with several positive signals in the market. Although there is still work to be done to recover the weaker sales during the first quarter, it is gratifying to see several positive signals: growth during the second quarter, continued strong development of recurring revenues, a growing order pipeline, and great interest in Miris HMA from both clinicians and researchers," says Strandberg.
- ·14.8.Soon Quarterly Report, so it would be nice if we could get some info about what the future looks out for the Company ;-).I thought the report would come today, but now it's in 7 days. Was it Nordnet that had the wrong date or have they postponed the report again? Do you know?
- ·13.8.Miris Holding develops and sells medical technology equipment for the analysis of human milk. The equipment is used in hospitals and Milk Banks to adapt nutrition for prematurely born children. Business model and market Unique position: The company is globally unique in having a medically approved analysis network/instrument for breast milk, which effectively removes direct competitors in the regulated market. Global reach: Over 500 instruments are installed in 54 countries via direct sales and distributors. Revenue streams: Hardware sales are supplemented by ongoing, recurring revenues from calibration, service, and consumables. Financial and technical status Growth vs. Liquidity: Miris shows progress in revenue and continuously receives orders from international research centers and hospitals, Financial status (Q1 2026) The latest financial figures from the company's Q1 2026 report show a company in a transitional phase characterized by macroeconomic headwinds, but with a stabilized cash position: Decline in net sales: Net sales for Q1 2026 amounted to 3,436 tkr. SEK, which is a decrease of approximately 25% compared to the same period in 2025 (4,585 tkr. SEK). Sluggishness in the American market: The company reports that the uncertain macroeconomic environment has led to longer decision-making processes and postponed investments at hospitals, especially in the USA. However, it has recently made exclusive agreements for market access in the Middle East, which strengthens Miris' position. Pipeline is intact: Management emphasizes that the postponed orders are not lost; the sales pipeline remains active. After the quarter's end, the company has seen increased activity in the form of new orders (including a new USA order in May 2026) and reinvestments from existing Nordic hospitals. Improved capital base: Through capital raises in 2025 (totaling approx. 25.3 million SEK), the company entered 2026 with a significantly stronger financial position, giving them peace of mind to mature the market. The medical potential in neonatal care The clinical foundation behind the Miris Human Milk Analyzer (HMA) is strong and addresses a critical, unmet need in neonatal intensive care units (NICU): Targeted Fortification: With Miris HMA, doctors can analyze the specific milk in minutes with just 3 ml of milk. This makes it possible to tailor the fortification (addition of extra protein or fat) precisely to the needs of each individual, prematurely born child. Clinical benefits: Studies and clinical feedback show that this precision nutrition reduces the risk of postnatal growth restriction, ensures better neurological development in extremely low birth weight (ELBW) infants, and can potentially shorten hospital stays, saving healthcare significant sums. Unique regulatory barrier: Miris remains the only company with FDA approval (obtained at the end of 2018) for clinical multi-analysis of breast milk in the USA. This provides an enormous competitive advantage, as it takes years for potential competitors to achieve the same medical validation. Summary and investment case The investment case in Miris balances a large medical potential with a sluggish commercial rollout: The medical value is undeniable, and the company owns the market regulatorily. The economic challenge, however, is hospitals' long budget and procurement cycles, which are further extended during economic uncertainty. However, the latest reports of reinvestments show that once a hospital has adopted the technology, it becomes an indispensable standard. Consumables business model Miris uses a classic "razor & blade" business model, which creates a growing stream of recurring revenues Primary sales: The hospital or milk bank makes a large one-time investment by purchasing the Miris Human Milk Analyzer (HMA) instrument itself, as well as associated hardware such as sonicators for sample preparation. Consumables: For the instrument to function correctly, deliver precise measurements, and comply with strict medical approvals, hospitals are forced to continuously purchase the company's own, specially developed consumables. These include: Miris Check: Calibration fluids for checking the instrument's zero setting. Miris Calibration Control Kit: Solutions with known concentrations of fat, protein, and carbohydrates for validation. Miris Cleaner: Specialized cleaning fluids that ensure milk residues do not damage the sensitive sensors. Miris Syringes: Specific disposable syringes approved for use in the machine. The more machines Miris gets installed around the world, the greater the automatic, ongoing sale of consumables becomes. These revenues generally have a higher margin (gross margin) than the hardware itself and give the company a more predictable earnings profile, which reduces dependence on long hospital budget cycles. The latest new orders are exciting and prove that Miris is on the right track. I look forward to the financial report.
- ·30.7.One can't really see orders pouring in, and very little info from the company :-).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt